

Krista L LanctÃ't

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/968888/publications.pdf>

Version: 2024-02-01

327
papers

19,079
citations

18465

62
h-index

16164

124
g-index

335
all docs

335
docs citations

335
times ranked

22749
citing authors

#	ARTICLE	IF	CITATIONS
1	Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada. <i>American Journal of Perinatology</i> , 2022, 39, 1668-1677.	0.6	8
2	Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 119-147.	0.6	28
3	Assessing the Longitudinal Relationship between Theta-Gamma Coupling and Working Memory Performance in Older Adults. <i>Cerebral Cortex</i> , 2022, 32, 1653-1667.	1.6	4
4	Inflammatory markers in type 2 diabetes with vs. without cognitive impairment; a systematic review and meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2022, 100, 55-69.	2.0	28
5	Pharmacological Management of Apathy in Dementia. <i>CNS Drugs</i> , 2022, 36, 143-165.	2.7	13
6	Time setting errors in the Clock Drawing Test are associated with both semantic and executive deficits. <i>Applied Neuropsychology Adult</i> , 2022, , 1-10.	0.7	3
7	Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects. <i>Neurochemistry International</i> , 2022, 152, 105250.	1.9	8
8	Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study. <i>Alzheimer's and Dementia</i> , 2022, 18, 2199-2208.	0.4	28
9	Altered central and blood glutathione in Alzheimer's disease and mild cognitive impairment: a meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 23.	3.0	22
10	Medical Cannabis Use Among Older Adults in Canada: Self-Reported Data on Types and Amount Used, and Perceived Effects. <i>Drugs and Aging</i> , 2022, 39, 153-163.	1.3	23
11	Therapeutic Passes and Post-Discharge Outcomes in a Psychiatric Inpatient Unit: A Retrospective Study. <i>Canadian Journal of Psychiatry</i> , 2022, , 070674372210879.	0.9	0
12	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: a meta-analysis. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 48.	3.0	42
13	Cognitive control, interference inhibition, and ordering of information during working memory in younger and older healthy adults. <i>GeroScience</i> , 2022, 44, 2291-2303.	2.1	1
14	Endosomal-Lysosomal and Autophagy Pathway in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1279-1292.	1.2	8
15	Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1203-1228.	1.2	7
16	Questioning the Meaning of a Change on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Noncomparable Scores and Item-Specific Effects Over Time. <i>Assessment</i> , 2021, 28, 1708-1722.	1.9	5
17	Neurobiologic Rationale for Treatment of Apathy in Alzheimer's Disease With Methylphenidate. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 51-62.	0.6	29
18	Measuring Apathy in Alzheimer's Disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A Comparison of Instruments. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 81-89.	0.6	9

#	ARTICLE	IF	CITATIONS
19	Depression and Increased Risk of Alzheimer's Dementia: Longitudinal Analyses of Modifiable Risk and Sex-Related Factors. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 917-926.	0.6	13
20	The association between placebo arm inclusion and adverse event rates in antidepressant randomized controlled trials: An examination of the Nocebo Effect. <i>Journal of Affective Disorders</i> , 2021, 280, 140-147.	2.0	3
21	Associations between brain amyloid accumulation and the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. <i>Neurobiology of Aging</i> , 2021, 100, 22-31.	1.5	22
22	The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ϵ 4 carrier status. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 43.	3.0	29
23	Glutathione Peroxidase Activity Is Altered in Vascular Cognitive Impairment-No Dementia and Is a Potential Marker for Verbal Memory Performance. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1285-1296.	1.2	3
24	Comparing cardiovascular risk factors in older persons with mild cognitive impairment and lifetime history of major depressive disorder. <i>International Psychogeriatrics</i> , 2021, , 1-7.	0.6	2
25	Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes. <i>Psychoneuroendocrinology</i> , 2021, 126, 105149.	1.3	14
26	Diagnostic criteria for apathy in neurocognitive disorders. <i>Alzheimer's and Dementia</i> , 2021, 17, 1892-1904.	0.4	71
27	Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 1324.	4.5	51
28	Mirtazapine for agitation in dementia: moving forward. <i>Lancet, The</i> , 2021, 398, 1462-1463.	6.3	2
29	Efficacy of non-invasive brain stimulation on global cognition and neuropsychiatric symptoms in Alzheimer's disease and mild cognitive impairment: A meta-analysis and systematic review. <i>Ageing Research Reviews</i> , 2021, 72, 101499.	5.0	34
30	Depression in type 2 diabetes: A systematic review and meta-analysis of blood inflammatory markers. <i>Psychoneuroendocrinology</i> , 2021, 134, 105448.	1.3	16
31	Impact of 12-week exercise program on biomarkers of gut barrier integrity in patients with coronary artery disease. <i>PLoS ONE</i> , 2021, 16, e0260165.	1.1	6
32	The potential roles of excitatory-inhibitory imbalances and the repressor element-1 silencing transcription factor in aging and aging-associated diseases. <i>Molecular and Cellular Neurosciences</i> , 2021, 117, 103683.	1.0	12
33	Sex differences in neuropsychiatric symptoms in Alzheimer's disease dementia: A meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
34	Oxidative stress mediates the effect of apathy on executive function in those at risk of vascular cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
35	Associations between the use of histamine ϵ 2 receptor antagonists vs. proton pump inhibitors and cognitive decline: A stratified longitudinal study in people with and without cognitive impairment. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
36	Serum oxylipins indicate subcortical ischemic vascular disease in patients with clinical stroke. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
37	Leukotriene receptor antagonist use is associated with slower cognitive decline in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
38	Lipid peroxidation mediates the relationship between cardiopulmonary fitness and depressive symptoms in people with coronary artery disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
39	Exercise priming with transcranial direct current stimulation: a study protocol for a randomized, parallel-design, sham-controlled trial in mild cognitive impairment and Alzheimer's disease. <i>BMC Geriatrics</i> , 2021, 21, 677.	1.1	5
40	<i>Canadian Stroke Best Practice Recommendations</i> : Mood, Cognition and Fatigue following Stroke, 6th edition update 2019. <i>International Journal of Stroke</i> , 2020, 15, 668-688.	2.9	121
41	Agitation, Oxidative Stress, and Cytokines in Alzheimer Disease: Biomarker Analyses From a Clinical Trial With Nabilone for Agitation. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 175-184.	1.2	23
42	Association Between Sphingolipids and Cardiopulmonary Fitness in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 671-679.	1.7	16
43	A Pilot Study Comparing Effects of Bifrontal Versus Bitemporal Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Mild Alzheimer Disease. <i>Journal of ECT</i> , 2020, 36, 211-215.	0.3	15
44	Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1143-1156.	1.2	39
45	Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 1256-1269.	0.6	40
46	Serum osteocalcin is associated with subjective stress in people with depression and type 2 diabetes. <i>Psychoneuroendocrinology</i> , 2020, 122, 104878.	1.3	2
47	Depression and Diabetes Mellitus Multimorbidity Is Associated With Loss of Independence and Dementia Poststroke. <i>Stroke</i> , 2020, 51, 3531-3540.	1.0	12
48	Respiratory Syncytial Virus Prophylaxis in Immunocompromised Children. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 539-545.	1.1	7
49	Relationships Between Serum Osteocalcin, Brain Derived Neurotrophic Factor and Subjective Stress in People With and Without Depression and Type 2 Diabetes Mellitus. <i>Biological Psychiatry</i> , 2020, 87, S437-S438.	0.7	0
50	Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33-35 Weeks Gestational Age in Quebec. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 694-699.	1.1	8
51	Neutrophil activation in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis of protein markers in blood and cerebrospinal fluid. <i>Ageing Research Reviews</i> , 2020, 62, 101130.	5.0	22
52	A Comparison of Respiratory Syncytial Viral Prophylaxis in Multiple Births versus Singletons in the Canadian Registry of Palivizumab. <i>American Journal of Perinatology</i> , 2020, 38, e129-e136.	0.6	0
53	Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role of APOE carrier status. <i>Alzheimer's and Dementia</i> , 2020, 16, 1663-1673.	0.4	51
54	Relationships between oral hypoglycemic drugs and memory decline in people with type 2 diabetes: A stratified longitudinal observational study. <i>Alzheimer's and Dementia</i> , 2020, 16, e041312.	0.4	1

#	ARTICLE	IF	CITATIONS
55	Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: Longitudinal associations with PET amyloid in the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2020, 16, e042014.	0.4	0
56	Investigating the relationship between neuropsychiatric symptoms and cognition in mild cognitive impairment and Alzheimer's disease patients undergoing an exercise-primed transcranial direct current stimulation clinical trial (The EXPRESS Study). <i>Alzheimer's and Dementia</i> , 2020, 16, e046158.	0.4	0
57	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. <i>Translational Psychiatry</i> , 2020, 10, 152.	2.4	102
58	Endostatin as a Mediator Between Endothelial Function and Cognitive Performance in Those at Risk for Vascular Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 1-11.	1.2	6
59	A peripheral neutrophil-related inflammatory factor predicts a decline in executive function in mild Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2020, 17, 84.	3.1	34
60	Antidepressant-placebo differences for specific adverse events in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , 2020, 267, 185-190.	2.0	13
61	Attentional impairments to novel images in dementia. , 2020, , 597-616.		0
62	The Role of Apathy and Depression on Verbal Learning and Memory Performance After Stroke. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 327-336.	0.3	15
63	Novel Pharmacologic Strategies for Treating Behavioral Disturbances in Alzheimer's Disease. <i>Current Behavioral Neuroscience Reports</i> , 2019, 6, 72-87.	0.6	1
64	Younger Age and Depressive Symptoms Predict High Risk of Generalized Anxiety After Stroke and Transient Ischemic Attack. <i>Stroke</i> , 2019, 50, 2359-2363.	1.0	23
65	Association Between Endothelial Function and Cognitive Performance in Patients With Coronary Artery Disease During Cardiac Rehabilitation. <i>Psychosomatic Medicine</i> , 2019, 81, 184-191.	1.3	17
66	Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100385.	0.5	14
67	Symptoms of depression and cognitive impairment in young adults after stroke/transient ischemic attack. <i>Psychiatry Research</i> , 2019, 279, 361-363.	1.7	15
68	24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer's Disease: Analyses from a Clinical Trial with Nabilone. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 21-31.	1.2	12
69	<p>The value of screening for cognition, depression, and frailty in patients referred for TAVI</p>. <i>Clinical Interventions in Aging</i> , 2019, Volume 14, 841-848.	1.3	26
70	Respiratory illness and respiratory syncytial virus hospitalization in infants with a tracheostomy following prophylaxis with palivizumab. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1561-1568.	1.3	4
71	Randomized Placebo-Controlled Trial of Nabilone for Agitation in Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1161-1173.	0.6	90
72	Validity of a novel screen for cognitive impairment and neuropsychiatric symptoms in cardiac rehabilitation. <i>BMC Geriatrics</i> , 2019, 19, 163.	1.1	5

#	ARTICLE	IF	CITATIONS
73	Plasma Sphingolipids Mediate a Relationship Between Type 2 Diabetes and Memory Outcomes in Patients with Coronary Artery Disease Undertaking Exercise. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 717-727.	1.2	5
74	Lithium Carbonate in a Poststroke Population. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 67-71.	0.7	11
75	Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia. <i>Drugs and Aging</i> , 2019, 36, 589-605.	1.3	24
76	The Roles of Apathy and Depression in Predicting Alzheimer Disease: A Longitudinal Analysis in Older Adults With Mild Cognitive Impairment. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 873-882.	0.6	61
77	Respiratory Syncytial Virus Prophylaxis in Neurologic and Muscular Disorders in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 775-780.	1.1	6
78	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019, 15, 292-312.	0.4	310
79	Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005â€“2017. <i>Clinical Infectious Diseases</i> , 2019, 69, 980-986.	2.9	7
80	Respiratory syncytial virus prophylaxis in infants with congenital airway anomalies compared to standard indications and complex medical disorders. <i>European Journal of Pediatrics</i> , 2019, 178, 377-385.	1.3	8
81	Screening for Post-Stroke Depression and Cognitive Impairment at Baseline Predicts Long-Term Patient-Centered Outcomes After Stroke. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2019, 32, 40-48.	1.2	42
82	Natural and Synthetic Cannabinoids for Agitation and Aggression in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	25
83	Sleep and Attention in Alzheimer's Disease. <i>Yale Journal of Biology and Medicine</i> , 2019, 92, 53-61.	0.2	7
84	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. <i>Molecular Neurobiology</i> , 2018, 55, 4195-4206.	1.9	279
85	Suicide deaths by intentional self-poisoning in people with cardiovascular disease. <i>General Hospital Psychiatry</i> , 2018, 52, 41-47.	1.2	7
86	The effect of white matter hyperintensities on verbal memory. <i>Neurology</i> , 2018, 90, e673-e682.	1.5	38
87	Cannabinoids for the treatment of neuropsychiatric symptoms, pain and weight loss in dementia. <i>Current Opinion in Psychiatry</i> , 2018, 31, 140-146.	3.1	15
88	Understanding the Link between Neuropsychiatric Symptoms and Cognitive Decline: Insights From Neuroimaging. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, S37.	0.6	0
89	Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1113-1118.	1.3	8
90	An International Approach to Enhancing a National Guideline on Driving and Dementia. <i>Current Psychiatry Reports</i> , 2018, 20, 16.	2.1	22

#	ARTICLE	IF	CITATIONS
91	Subcortical hyperintensities in the cholinergic system are associated with improvements in executive function in older adults with coronary artery disease undergoing cardiac rehabilitation. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 279-287.	1.3	8
92	Prevalence, neurobiology, and treatments for apathy in prodromal dementia. <i>International Psychogeriatrics</i> , 2018, 30, 177-184.	0.6	41
93	Social inappropriateness in neurodegenerative disorders. <i>International Psychogeriatrics</i> , 2018, 30, 197-207.	0.6	66
94	Global grey matter volume in adult bipolar patients with and without lithium treatment: A meta-analysis. <i>Journal of Affective Disorders</i> , 2018, 225, 599-606.	2.0	55
95	Apathy, not depressive symptoms, as a predictor of semantic and phonemic fluency task performance in stroke and transient ischemic attack. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 449-461.	0.8	19
96	Cognitive Outcomes After Transcatheter Aortic Valve Implantation: A Metaanalysis. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 254-262.	1.3	27
97	Adherence and outcomes: a systematic review of palivizumab utilization. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 27-42.	1.0	31
98	F4â€02â€04: NABILONE SIGNIFICANTLY IMPROVES AGITATION/AGGRESSION IN PATIENTS WITH MODERATEâ€TOâ€SEVERE AD: PRELIMINARY RESULTS OF A PLACEBOâ€CONTROLLED, DOUBLEâ€BLIND, CROSSâ€OVER TRIAL. <i>Alzheimer's and Dementia</i> , 2018, 14, P1385.	1.0	5
99	Effect of Methylphenidate for Apathy on Visual Attention Scanning Behavior: a Pilot Study. <i>Canadian Geriatrics Journal</i> , 2018, 21, 139-142.	0.7	2
100	Psychometric Properties of Apathy Scales in Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1065-1082.	1.2	22
101	Longitudinal associations between 4-hydroxynonenal and depression in coronary artery disease patients. <i>Psychiatry Research</i> , 2018, 270, 219-224.	1.7	7
102	The effect of exercise on resting concentrations of peripheral brain-derived neurotrophic factor (BDNF) in major depressive disorder: A meta-analysis. <i>Journal of Psychiatric Research</i> , 2018, 105, 123-131.	1.5	34
103	Ceramide Accumulation Is Associated with Declining Verbal Memory in Coronary Artery Disease Patients: An Observational Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1235-1246.	1.2	10
104	Novel Phospholipid Signature of Depressive Symptoms in Patients With Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	11
105	Biomarkers of agitation and aggression in Alzheimer's disease: A systematic review. , 2018, 14, 1344-1376.		31
106	Psychometric properties of apathy scales in Parkinson's disease: a systematic review. <i>Neurodegenerative Disease Management</i> , 2018, 8, 267-282.	1.2	8
107	Detection of Apathy in Alzheimer Patients by Analysing Visual Scanning Behaviour with RNNs. , 2018, , .		6
108	Centre- versus home-based exercise among people with mci and mild dementia: study protocol for a randomized parallel-group trial. <i>BMC Geriatrics</i> , 2018, 18, 27.	1.1	10

#	ARTICLE	IF	CITATIONS
109	Pharmacological interventions for apathy in Alzheimer's disease. The Cochrane Library, 2018, 2018, CD012197.	1.5	57
110	Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression. Journal of Clinical Psychiatry, 2018, 80, .	1.1	20
111	Apathy associated with neurocognitive disorders: Recent progress and future directions. Alzheimer's and Dementia, 2017, 13, 84-100.	0.4	167
112	The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. Journal of Alzheimer's Disease, 2017, 56, 929-938.	1.2	306
113	Ceramides and depression: A systematic review. Journal of Affective Disorders, 2017, 213, 35-43.	2.0	64
114	Comparing First- and Second-year Palivizumab Prophylaxis in Patients With Hemodynamically Significant Congenital Heart Disease in the CARESS Database (2005-2015). Pediatric Infectious Disease Journal, 2017, 36, 445-450.	1.1	15
115	The effect of acute exercise on blood concentrations of brain-derived neurotrophic factor in healthy adults: a meta-analysis. European Journal of Neuroscience, 2017, 46, 1635-1646.	1.2	198
116	Good Outcome Isn't Good Enough. Stroke, 2017, 48, 1688-1690.	1.0	116
117	Update on the Risk of Motor Vehicle Collision or Driving Impairment with Dementia: A Collaborative International Systematic Review and Meta-Analysis. American Journal of Geriatric Psychiatry, 2017, 25, 1376-1390.	0.6	38
118	Peripheral inflammatory markers indicate microstructural damage within periventricular white matter hyperintensities in Alzheimer's disease: A preliminary report. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 56-60.	1.2	41
119	Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease. Neurodegenerative Disease Management, 2017, 7, 317-329.	1.2	30
120	Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy. Pediatric Infectious Disease Journal, 2017, 36, 2-8.	1.1	28
121	Peripheral inflammatory markers in Alzheimer's disease: a systematic review and meta-analysis of 175 studies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 876-882.	0.9	336
122	Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 440-449.	1.8	240
123	A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise. Journal of Alzheimer's Disease, 2017, 60, 829-841.	1.2	17
124	First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015). European Journal of Pediatrics, 2017, 176, 413-422.	1.3	12
125	Peripheral lipid oxidative stress markers are related to vascular risk factors and subcortical small vessel disease. Neurobiology of Aging, 2017, 59, 91-97.	1.5	28
126	Oxidative stress predicts depressive symptom changes with omega-3 fatty acid treatment in coronary artery disease patients. Brain, Behavior, and Immunity, 2017, 60, 136-141.	2.0	25

#	ARTICLE	IF	CITATIONS
127	Plasma sphingolipids and depressive symptoms in coronary artery disease. <i>Brain and Behavior</i> , 2017, 7, e00836.	1.0	21
128	Lipid Peroxidation Markers in Coronary Artery Disease Patients with Possible Vascular Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 885-896.	1.2	14
129	[P3â€“210]: PLASMA SPHINGOLIPID RATIOS AND VERBAL MEMORY PERFORMANCE IN A CORONARY ARTERY DISEASE POPULATION AT RISK FOR VASCULAR COGNITIVE IMPAIRMENT (VCI) AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1016.	0.4	0
130	[P3â€“239]: A LIPIDOMICS APPROACH TO ASSESS PLASMA SPHINGOLIPIDS AS PREDICTORS OF VERBAL MEMORY PERFORMANCE IN CORONARY ARTERY DISEASE PATIENTS UNDERTAKING CARDIAC REHABILITATION: A C18:0 SIGNATURE FOR COGNITIVE RESPONSE TO EXERCISE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1031.	0.4	0
131	[O1â€“01â€“06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P184.	0.4	0
132	Baseline Oxidative Stress Is Associated with Memory Changes in Omega-3 Fatty Acid Treated Coronary Artery Disease Patients. <i>Cardiovascular Psychiatry and Neurology</i> , 2017, 2017, 1-7.	0.8	8
133	The â€œDOCâ€•screen: Feasible and valid screening for depression, Obstructive Sleep Apnea (OSA) and cognitive impairment in stroke prevention clinics. <i>PLoS ONE</i> , 2017, 12, e0174451.	1.1	23
134	Inflammatory Markers and Brain-Derived Neurotrophic Factor as Potential Bridges Linking Bipolar Disorder and Cardiovascular Risk Among Adolescents. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e286-e293.	1.1	33
135	Pharmacotherapy of Dementia. <i>Mental Health and Illness Worldwide</i> , 2017, , 455-480.	0.1	0
136	Serum low-density lipoprotein levels, statin use, and cognition in patients with coronary artery disease. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 2913-2920.	1.0	8
137	Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review. <i>Current Molecular Medicine</i> , 2016, 16, 137-164.	0.6	33
138	Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 373-381.	1.2	8
139	Pharmacological interventions for apathy in Alzheimer's disease. <i>The Cochrane Library</i> , 2016, , .	1.5	3
140	Visual Selective Attention Toward Novel Stimuli Predicts Cognitive Decline in Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1339-1349.	1.2	25
141	P1â€“190: The Association Between Endothelial Dysfunction and Memory Performance in Patients With Coronary Artery Disease Undertaking Cardiac Rehabilitation. <i>Alzheimer's and Dementia</i> , 2016, 12, P476.	0.4	0
142	P1â€“371: The Association Between Apathy and Executive Function in Coronary Artery Disease Patients is Modified By Endothelial Dysfunction. <i>Alzheimer's and Dementia</i> , 2016, 12, P573.	0.4	0
143	P2â€“403: Targeting MCI with Cardiac Rehabilitation Exercise: A Feasibility Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P799.	0.4	0
144	P3-181: Evaluating the Relationship Between Markers of Oxidative Stress and Cognitive Performance in Coronary Artery Disease Patients. , 2016, 12, P889-P890.		0

#	ARTICLE	IF	CITATIONS
145	P1-057: Lithium Carbonate and Verbal Memory Improvement in Post-Stroke Patients: Preliminary Report. , 2016, 12, P423-P424.		0
146	Apathy and Attentional Biases in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 837-846.	1.2	19
147	Evidence for Inflammation-Associated Depression. Current Topics in Behavioral Neurosciences, 2016, 31, 3-30.	0.8	68
148	Post-stroke depression, obstructive sleep apnea, and cognitive impairment: Rationale for, and barriers to, routine screening. International Journal of Stroke, 2016, 11, 509-518.	2.9	81
149	Considering new treatment paradigms for neuropsychiatric symptoms of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1031-1032.	0.4	2
150	Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2016, 17, 2417-2429.	0.9	18
151	Omega-3: The Mild Behavioral Impairment Checklist (MBI-C): a New Rating Scale for Neuropsychiatric Symptoms as Early Manifestations of Neurodegenerative Disease. Alzheimer's and Dementia, 2016, 12, P209.	0.4	0
152	Palivizumab Adherence and Outcomes in Canadian Aboriginal Children. Pediatric Infectious Disease Journal, 2016, 35, 1187-1193.	1.1	3
153	Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease. Journal of Clinical Psychopharmacology, 2016, 36, 436-444.	0.7	39
154	Omega-3/omega-6 fatty acid ratios in different phospholipid classes and depressive symptoms in coronary artery disease patients. Brain, Behavior, and Immunity, 2016, 53, 54-58.	2.0	8
155	Validating a Pragmatic Approach to Cognitive Screening in Stroke Prevention Clinics Using the Montreal Cognitive Assessment. Stroke, 2016, 47, 807-813.	1.0	20
156	Bias in Peripheral Depression Biomarkers. Psychotherapy and Psychosomatics, 2016, 85, 81-90.	4.0	46
157	Suicide in males and females with cardiovascular disease and comorbid depression. Journal of Affective Disorders, 2016, 197, 88-93.	2.0	20
158	A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease. Journal of the American Medical Directors Association, 2016, 17, 142-147.	1.2	47
159	Pharmacotherapy of Dementia. Mental Health and Illness Worldwide, 2016, , 1-26.	0.1	2
160	The Effect of Exercise Training on Resting Concentrations of Peripheral Brain-Derived Neurotrophic Factor (BDNF): A Meta-Analysis. PLoS ONE, 2016, 11, e0163037.	1.1	212
161	The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer's Disease. Current Pharmaceutical Design, 2016, 22, 6152-6166.	0.9	179
162	Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. Current Alzheimer Research, 2016, 13, 1134-1144.	0.7	19

#	ARTICLE	IF	CITATIONS
163	Dr Mazereeuw and Colleagues Reply. Journal of Clinical Psychiatry, 2016, 77, e1006-e1006.	1.1	0
164	Cholinesterase Inhibitor Discontinuation in Institutionalized Persons with Moderate to Severe AD: Results of a Double-Blind, Placebo Controlled Trial. American Journal of Geriatric Psychiatry, 2015, 23, S172-S173.	0.6	2
165	<i>Canadianâ€¦Strokeâ€¦Bestâ€¦Practiceâ€¦Recommendations: Mood, Cognition and Fatigue following Stroke</i> Practice Guidelines, Update 2015. International Journal of Stroke, 2015, 10, 1130-1140.	2.9	88
166	Latrepidine for Alzheimer's disease. The Cochrane Library, 2015, 2015, CD009524.	1.5	18
167	Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. Journal of Alzheimer's Disease, 2015, 47, 669-679.	1.2	49
168	Risk Factors for Progression of Alzheimer Disease in a Canadian Population: The Canadian Outcomes Study in Dementia (COSID). Canadian Journal of Psychiatry, 2015, 60, 189-199.	0.9	17
169	Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab. Pediatric Infectious Disease Journal, 2015, 34, e290-e297.	1.1	35
170	A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatric Disease and Treatment, 2015, 11, 2479.	1.0	44
171	Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a hypothesis-generating study. Neuropsychiatric Disease and Treatment, 2015, 11, 2309.	1.0	13
172	Serious Adverse Events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for Respiratory Syncytial Virus Prevention. PLoS ONE, 2015, 10, e0134711.	1.1	20
173	Cognitive Outcomes following Transcatheter Aortic Valve Implantation: A Systematic Review. Cardiovascular Psychiatry and Neurology, 2015, 2015, 1-8.	0.8	19
174	Exploring Visual Selective Attention towards Novel Stimuli in Alzheimer's Disease Patients. Dementia and Geriatric Cognitive Disorders Extra, 2015, 5, 492-502.	0.6	27
175	Reply to: Serum Zinc and the Risk of Depression in Men: Observations from a 20-Year Follow-up Study. Biological Psychiatry, 2015, 77, e13-e14.	0.7	7
176	Caregiversâ€™ willingness-to-pay for Alzheimerâ€™s disease medications in Canada. Dementia, 2015, 14, 63-79.	1.0	6
177	White Matter Microstructural Integrity Is Associated with Executive Function and Processing Speed in Older Adults with Coronary Artery Disease. American Journal of Geriatric Psychiatry, 2015, 23, 754-763.	0.6	49
178	Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Review of Respiratory Medicine, 2015, 9, 779-799.	1.0	15
179	Cannabinoids for the Treatment of Agitation and Aggression in Alzheimerâ€™s Disease. CNS Drugs, 2015, 29, 615-623.	2.7	47
180	A Novel Rating Scale for the Measurement of Apathy in Institutionalized Persons with Dementia: The APADEM-NH. American Journal of Geriatric Psychiatry, 2015, 23, 149-159.	0.6	16

#	ARTICLE	IF	CITATIONS
181	Cholinesterase Inhibitor Discontinuation in Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2015, 76, e1424-e1431.	1.1	56
182	Is Cardiac Rehabilitation Exercise Feasible for People with Mild Cognitive Impairment?. <i>Canadian Geriatrics Journal</i> , 2015, 18, 65-72.	0.7	10
183	Cardiopulmonary Fitness Correlates with Regional Cerebral Grey Matter Perfusion and Density in Men with Coronary Artery Disease. <i>PLoS ONE</i> , 2014, 9, e91251.	1.1	18
184	Kynurenine and depressive symptoms in a poststroke population. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1827.	1.0	21
185	Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. <i>International Psychogeriatrics</i> , 2014, 26, 239-246.	0.6	40
186	Hospitalization for Respiratory Syncytial Virus Illness in Down Syndrome Following Prophylaxis With Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, e29-e33.	1.1	25
187	Assessing Cognitive Effects of Anticholinergic Medications in Patients With Coronary Artery Disease. <i>Psychosomatics</i> , 2014, 55, 61-68.	2.5	19
188	Respiratory Syncytial Virus Prophylaxis in Down Syndrome: A Prospective Cohort Study. <i>Pediatrics</i> , 2014, 133, 1031-1037.	1.0	42
189	Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study. <i>Journal of Neuroinflammation</i> , 2014, 11, 119.	3.1	8
190	The Platelet Activating Factor PC(O-18:3/2:0) is Associated with Apathy Independently of Depressive Symptoms in Depressed Patients with Coronary Artery Disease. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, S110.	0.6	0
191	Predictors of readmission to a psychiatry inpatient unit. <i>Comprehensive Psychiatry</i> , 2014, 55, 426-430.	1.5	36
192	Treatment effects in multiple cognitive domains in Alzheimer's disease: a two-year cohort study. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 48.	3.0	11
193	P4-180: DESIGN OF THE SARTAN-AD TRIAL. , 2014, 10, P854-P855.		0
194	Sub-threshold cognitive impairment in multiple sclerosis: the association with cognitive reserve. <i>Journal of Neurology</i> , 2013, 260, 2256-2261.	1.8	26
195	Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia. <i>Alzheimer's and Dementia</i> , 2013, 9, e96-e105.	0.4	66
196	Zinc in Depression: A Meta-Analysis. <i>Biological Psychiatry</i> , 2013, 74, 872-878.	0.7	180
197	Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study. <i>BMC Geriatrics</i> , 2013, 13, 135.	1.1	16
198	Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S5.	3.0	88

#	ARTICLE	IF	CITATIONS
199	Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia: The Apathy in Dementia Methylphenidate Trial (ADMET). <i>American Journal of Geriatric Psychiatry</i> , 2013, 21, 549-559.	0.6	13
200	Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future. <i>Alzheimer's and Dementia</i> , 2013, 9, 602-608.	0.4	292
201	Platelet activating factors in depression and coronary artery disease: A potential biomarker related to inflammatory mechanisms and neurodegeneration. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1611-1621.	2.9	40
202	Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 911-929.	2.9	91
203	Interleukin-17 in post-stroke neurodegeneration. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 436-447.	2.9	73
204	The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. <i>Journal of Medical Economics</i> , 2013, 16, 115-124.	1.0	17
205	Assessing the validity of a computer-generated cognitive screening instrument for patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1905-1912.	1.4	30
206	Higher Cortisol Predicts Less Improvement in Verbal Memory Performance after Cardiac Rehabilitation in Patients with Coronary Artery Disease. <i>Cardiovascular Psychiatry and Neurology</i> , 2013, 2013, 1-8.	0.8	12
207	Respiratory-Related Hospitalizations following Prophylaxis in the Canadian Registry for Palivizumab (2005-2012) Compared to Other International Registries. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-15.	3.3	34
208	Safety and Efficacy of Methylphenidate for Apathy in Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 810-816.	1.1	155
209	Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease. <i>Canadian Geriatrics Journal</i> , 2013, 16, 180-185.	0.7	10
210	CARESS. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 213.	1.1	3
211	Serotonergic Function and Treatment of Behavioral and Psychological Symptoms of Frontotemporal Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 789-797.	0.6	97
212	A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 2703-2711.	1.3	25
213	Effects of omega-3 fatty acids on cognitive performance: a meta-analysis. <i>Neurobiology of Aging</i> , 2012, 33, 1482.e17-1482.e29.	1.5	190
214	Exercise intervention and inflammatory markers in coronary artery disease: A meta-analysis. <i>American Heart Journal</i> , 2012, 163, 666-676.e3.	1.2	68
215	Computerized cognitive testing for patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2012, 1, 196-201.	0.9	14
216	Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease Relieve Caregiver Burden?. <i>Drugs and Aging</i> , 2012, 29, 167-179.	1.3	33

#	ARTICLE	IF	CITATIONS
217	A review of cost-effectiveness of palivizumab for respiratory syncytial virus. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 553-567.	0.7	20
218	Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. <i>European Journal of Pediatrics</i> , 2012, 171, 833-841.	1.3	37
219	Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	0.6	3
220	Sponsorship, Antidepressant Dose, and Outcome in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2012, 73, e277-e287.	1.1	12
221	Changes in Nursing Burden Following Memantine for Agitation and Aggression in Long-Term Care Residents with Moderate to Severe Alzheimer's Disease. <i>CNS Drugs</i> , 2011, 25, 425-433.	2.7	26
222	Current and Emerging Drug Treatment Options for Alzheimer's Disease. <i>Drugs</i> , 2011, 71, 2031-2065.	4.9	196
223	Memantine in dementia: a review of the current evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 787-800.	0.9	53
224	Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type. <i>Ageing Research Reviews</i> , 2011, 10, 404-12.	5.0	87
225	Brain derived neurotrophic factor, cardiopulmonary fitness and cognition in patients with coronary artery disease. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1264-1271.	2.0	39
226	The Role of Dopamine in Symptoms and Treatment of Apathy in Alzheimer's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 411-427.	1.9	99
227	A Decade of Respiratory Syncytial Virus Epidemiology and Prophylaxis: Translating Evidence into Everyday Clinical Practice. <i>Canadian Respiratory Journal</i> , 2011, 18, e10-e19.	0.8	68
228	The Effects of Donepezil on Computer-Simulated Driving Ability Among Healthy Older Adults. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 587-592.	0.7	2
229	CARESS: The Canadian Registry of Palivizumab. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 651-655.	1.1	44
230	Verbal Memory Performance and Completion of Cardiac Rehabilitation in Patients With Coronary Artery Disease. <i>Psychosomatic Medicine</i> , 2011, 73, 580-587.	1.3	12
231	Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts. <i>International Psychogeriatrics</i> , 2011, 23, 539-545.	0.6	25
232	Long-term use of cholinesterase inhibitors: till death do us part?. <i>Neurodegenerative Disease Management</i> , 2011, 1, 7-9.	1.2	1
233	The relationship between indoleamine 2,3-dioxygenase activity and post-stroke cognitive impairment. <i>Journal of Neuroinflammation</i> , 2011, 8, 17.	3.1	79
234	Pediatric Cancer Rates After Universal Folic Acid Flour Fortification In Ontario. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 60-65.	1.0	35

#	ARTICLE	IF	CITATIONS
235	Validity and Responsiveness to Change of Clinically Derived MDS Scales in Alzheimer Disease Outcomes Research. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 67-72.	1.2	21
236	Lithium and its Neuroprotective and Neurotrophic Effects: Potential Treatment for Post-Ischemic Stroke Sequelae. <i>Current Drug Targets</i> , 2011, 12, 243-255.	1.0	37
237	Are Vascular Risk Factors Associated With Post-Stroke Depressive Symptoms?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2011, 24, 215-221.	1.2	18
238	Major Depressive Disorder Predicts Completion, Adherence, and Outcomes in Cardiac Rehabilitation. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1181-1188.	1.1	76
239	Efficacy and Tolerability of Antidepressants for Treatment of Depression in Coronary Artery Disease: A Meta-Analysis. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 91-99.	0.9	52
240	The Relation between Disease Severity and Cost of Caring for Patients with Alzheimer Disease in Canada. <i>Canadian Journal of Psychiatry</i> , 2010, 55, 768-775.	0.9	28
241	Cardiopulmonary Fitness Is Associated with Cognitive Performance in Patients with Coronary Artery Disease. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 1519-1525.	1.3	29
242	The Relationship Between Inflammatory Markers and Post Stroke Cognitive Impairment. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2010, 23, 199-205.	1.2	97
243	Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. <i>Brain Injury</i> , 2010, 24, 959-969.	0.6	53
244	A Meta-Analysis of Cytokines in Major Depression. <i>Biological Psychiatry</i> , 2010, 67, 446-457.	0.7	3,771
245	A Meta-Analysis of Cytokines in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2010, 68, 930-941.	0.7	851
246	Changing costs and the impact on RSV prophylaxis. <i>Journal of Medical Economics</i> , 2010, 13, 705-708.	1.0	23
247	The cost effectiveness of palivizumab: a systematic review of the evidence. <i>Journal of Medical Economics</i> , 2010, 13, 453-463.	1.0	39
248	The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimer's Disease. <i>CNS Drugs</i> , 2010, 24, 909-927.	2.7	50
249	Does Inclusion of a Placebo Arm Influence Response to Active Antidepressant Treatment in Randomized Controlled Trials?. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 270-279.	1.1	179
250	A Randomized Controlled Trial of Antidepressant Continuation for Major Depression Following Traumatic Brain Injury. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1125-1130.	1.1	31
251	Relationship between hair cortisol concentrations and depressive symptoms in patients with coronary artery disease. <i>Neuropsychiatric Disease and Treatment</i> , 2010, 6, 393-400.	1.0	64
252	Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection. <i>Canadian Family Physician</i> , 2010, 56, 988-91.	0.1	1

#	ARTICLE	IF	CITATIONS
253	Review: Therapy for Alzheimer's disease: how effective are current treatments?. Therapeutic Advances in Neurological Disorders, 2009, 2, 163-180.	1.5	95
254	A SPECT Study of Sleep Disturbance and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2009, 27, 254-259.	0.7	19
255	Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. Psychoneuroendocrinology, 2009, 34, 1560-1566.	1.3	48
256	Assessing the validity of deriving clinical dementia rating (CDR) global scores from independently obtained functional rating scale (FRS) scores in vascular dementia with and without Alzheimer's disease. International Journal of Geriatric Psychiatry, 2009, 24, 1174-1176.	1.3	6
257	The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. Journal of Medical Economics, 2009, 12, 361-370.	1.0	33
258	Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Current Medical Research and Opinion, 2009, 25, 1631-1633.	0.9	1
259	Risk Factors and Viruses Associated With Hospitalization Due to Lower Respiratory Tract Infections in Canadian Inuit Children. Pediatric Infectious Disease Journal, 2009, 28, 697-701.	1.1	66
260	Comparison of the Cost of Hospitalization for Respiratory Syncytial Virus Disease Versus Palivizumab Prophylaxis in Canadian Inuit Infants. Pediatric Infectious Disease Journal, 2009, 28, 702-706.	1.1	52
261	Factor Analysis of the Rivermead Post-Concussion Symptoms Questionnaire in Mild-to-Moderate Traumatic Brain Injury Patients. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 181-188.	0.9	57
262	A brief history of poststroke depression neuroimaging. Aging Health, 2009, 5, 79-88.	0.3	2
263	Benzodiazepine Use and Driving. Journal of Clinical Psychiatry, 2009, 70, 663-673.	1.1	93
264	A functional neuroimaging study of appetite loss in Alzheimer's disease. Journal of the Neurological Sciences, 2008, 271, 97-103.	0.3	40
265	Commentary: AÎ²(1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT2A levels. Experimental Neurology, 2008, 212, 251-254.	2.0	3
266	Apathy Associated with Alzheimer Disease: Use of Dextroamphetamine Challenge. American Journal of Geriatric Psychiatry, 2008, 16, 551-557.	0.6	40
267	The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis. Current Medical Research and Opinion, 2008, 24, 3223-3237.	0.9	63
268	Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. Cmaj, 2008, 179, 787-793.	0.9	67
269	An open-label study of citalopram for major depression following traumatic brain injury. Journal of Psychopharmacology, 2008, 22, 860-864.	2.0	64
270	Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. Cmaj, 2008, 179, 1019-1026.	0.9	130

#	ARTICLE	IF	CITATIONS
271	The serotonin transporter polymorphisms and major depression following traumatic brain injury. <i>Brain Injury</i> , 2008, 22, 471-479.	0.6	29
272	The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort. <i>International Psychogeriatrics</i> , 2008, 20, 1141.	0.6	21
273	Methylphenidate for the Treatment of Apathy in Alzheimer Disease. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 296-301.	0.7	124
274	Management of behavioural and psychological symptoms of dementia and acquired brain injury. , 2008, , 187-216.		6
275	Relationship between cardiopulmonary fitness and depressive symptoms in cardiac rehabilitation patients with coronary artery disease. <i>Acta Dermato-Venereologica</i> , 2008, 40, 213-218.	0.6	18
276	A Placebo-Controlled Trial of Valproate for Agitation and Aggression in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 116-119.	0.7	82
277	Adverse Drug Events in Cognitively Impaired Elderly Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 395-400.	0.7	39
278	A SPECT Study of Apathy in Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 65-72.	0.7	112
279	Strategic Subcortical Hyperintensities in Cholinergic Pathways and Executive Function Decline in Treated Alzheimer Patients. <i>Archives of Neurology</i> , 2007, 64, 266.	4.9	73
280	Efficacy and Safety of Antidepressants for Treatment of Depression in Alzheimer's Disease: A Metaanalysis. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 248-255.	0.9	121
281	Pharmacologic Management of Neuropsychiatric Symptoms of Alzheimer Disease. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 630-646.	0.9	62
282	Behavioral correlates of GABAergic disruption in Alzheimer's disease. <i>International Psychogeriatrics</i> , 2007, 19, 151.	0.6	48
283	Commentary on "Health economics and the value of therapy in Alzheimer's disease: Cholinesterase inhibitors in Alzheimer's disease-Evidence-based or evidence-biased?". , 2007, 3, 177-179.		0
284	Management of mild to moderate Alzheimer's disease and dementia. <i>Alzheimer's and Dementia</i> , 2007, 3, 355-384.	0.4	67
285	A Positron Emission Tomography Study of 5-Hydroxytryptamine-1A Receptors in Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2007, 15, 888-898.	0.6	45
286	Serotonin-1A receptors in frontotemporal dementia compared with controls. <i>Psychiatry Research - Neuroimaging</i> , 2007, 156, 247-250.	0.9	33
287	Atypical Antipsychotics for Neuropsychiatric Symptoms of Dementia. <i>Drug Safety</i> , 2006, 29, 833-843.	1.4	40
288	The contribution of neuropsychiatric symptoms to the cost of dementia care. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 972-976.	1.3	190

#	ARTICLE	IF	CITATIONS
289	Perceptions of Natural Health Products Among Patients Attending a Memory Clinic. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2006, 21, 156-163.	0.9	13
290	Dr. Herrmann and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2005, 162, 1027-a-1028.	4.0	2
291	Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. <i>BMJ: British Medical Journal</i> , 2005, 331, 1169.	2.4	908
292	Review: donepezil improves cognitive and global function in people with mild to moderate Alzheimer's disease. <i>Evidence-Based Mental Health</i> , 2005, 8, 15-15.	2.2	0
293	Erectile dysfunction in spinal cord injury: a cost-utility analysis. <i>Journal of Rehabilitation Medicine</i> , 2005, 37, 358-364.	0.8	23
294	Antidepressant Use during Pregnancy and the Rates of Spontaneous Abortions: A Meta-Analysis. <i>Annals of Pharmacotherapy</i> , 2005, 39, 803-809.	0.9	165
295	Do Atypical Antipsychotics Cause Stroke?. <i>CNS Drugs</i> , 2005, 19, 91-103.	2.7	143
296	Atypical Antipsychotics and Risk of Cerebrovascular Accidents. <i>American Journal of Psychiatry</i> , 2004, 161, 1113-1115.	4.0	262
297	The Role of Norepinephrine in the Behavioral and Psychological Symptoms of Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004, 16, 261-276.	0.9	93
298	Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer's Disease Patients. <i>Journal of Psychopharmacology</i> , 2004, 18, 215-220.	2.0	25
299	Medial Temporal Hypoperfusion and Aggression in Alzheimer Disease. <i>Archives of Neurology</i> , 2004, 61, 1731.	4.9	49
300	Growth hormone response to clonidine predicts aggression in Alzheimer's disease. <i>Psychoneuroendocrinology</i> , 2004, 29, 1192-1197.	1.3	21
301	The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. <i>Expert Opinion on Drug Safety</i> , 2004, 3, 425-440.	1.0	86
302	GABAergic Function in Alzheimer's Disease: Evidence for Dysfunction and Potential as a Therapeutic Target for the Treatment of Behavioural and Psychological Symptoms of Dementia. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 439-453.	0.9	169
303	The Cost-Benefit of Cholinesterase Inhibitors in Mild to Moderate Dementia. <i>CNS Drugs</i> , 2003, 17, 1045-1057.	2.7	21
304	Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. <i>Journal of Psychiatry and Neuroscience</i> , 2003, 28, 13-26.	1.4	39
305	Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. <i>Cmaj</i> , 2003, 169, 557-64.	0.9	104
306	Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 512-518.	1.1	63

#	ARTICLE	IF	CITATIONS
307	Potential Interactions between Herbal Medicines and Conventional Drug Therapies Used by Older Adults Attending a Memory Clinic. <i>Drugs and Aging</i> , 2002, 19, 879-886.	1.3	87
308	Central Serotonergic Activity is Related to the Aggressive Behaviors of Alzheimer's Disease. <i>Neuropsychopharmacology</i> , 2002, 27, 646-54.	2.8	42
309	Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 531-541.	1.3	52
310	Clinical and Economic Factors in the Treatment of Behavioural and Psychological Symptoms of Dementia. <i>Drugs and Aging</i> , 2001, 18, 527-550.	1.3	24
311	Herbal-drug therapy interactions: A focus on dementia. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2001, 4, 29-34.	1.3	37
312	Role of Serotonin in the Behavioral and Psychological Symptoms of Dementia. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 5-21.	0.9	98
313	Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: Time for a Different Paradigm?. <i>Pharmacotherapy</i> , 2001, 21, 74-102.	1.2	23
314	Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. <i>Journal of Medical Economics</i> , 2001, 4, 137-156.	1.0	24
315	Donepezil for behavioural disorders associated with Lewy bodies: a case series. , 2000, 15, 338-345.		86
316	Drugs Mimicking Dementia. <i>CNS Drugs</i> , 2000, 14, 381-390.	2.7	11
317	Efficacy and Safety of Neuroleptics in Behavioral Disorders Associated With Dementia. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 550-561.	1.1	113
318	Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 58, 692-698.	2.3	79
319	Improving the Diagnosis of Hypersensitivity Reactions Associated with Sulfonamides. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 1228-1233.	1.0	20
320	Enhanced differential diagnosis of anticonvulsant hypersensitivity reactions by an integrated Bayesian and biochemical approach. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 564-575.	2.3	23
321	Computer-Assisted Evaluation of Adverse Events Using a Bayesian Approach. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 142-147.	1.0	33
322	Bayesian evaluation of sequential cases of Neutropenia. <i>Pharmacoepidemiology and Drug Safety</i> , 1993, 2, S1-S6.	0.9	3
323	Citalopram decreases desirability, liking, and consumption of alcohol in alcohol-dependent drinkers. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 51, 729-739.	2.3	110
324	Advances in the Diagnosis of Adverse Drug Reactions. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 897-904.	1.0	83

#	ARTICLE	IF	CITATIONS
325	Recent Developments in Computer-Assisted Diagnosis of Putative Adverse Drug Reactions. Drug Safety, 1991, 6, 315-322.	1.4	14
326	A Bayesian Assessment of Idiosyncratic Adverse Reactions to New Drugs: Guillain-Barré Syndrome and Zimeldine. Journal of Clinical Pharmacology, 1990, 30, 174-180.	1.0	24
327	The Bayesian Differential Diagnosis of Neutropenia Associated with Antiarrhythmic Agents. Journal of Clinical Pharmacology, 1990, 30, 1120-1127.	1.0	27